CompletedPhase 2

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

United States210 participantsStarted 2010-05

Plain-language summary

This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female patients \> 18 * Documented acute bacterial skin and skin structure infection Exclusion Criteria: * Uncomplicated skin and skin structure infection

What they're measuring

Clinical Response

Timeframe: Test of Cure (TOC), 7 - 14 days post final treatment

Clinical Response

Timeframe: Test of Cure (TOC), 7 - 14 days post final treatment

Trial details

NCT IDNCT01119105

SponsorNabriva Therapeutics AG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-12-31

Results submitted2020-10-05

View on ClinicalTrials.gov More Bacterial Infections trials